Abemaciclib + Pembrolizumab In Glioblastoma

Summary

This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. This study will involve participants with recurrent glioblastoma at their first relapse enrolled in two arms including patients who require reoperation and patients not requiring surgery. This research study involves a combination of two drugs: * Pembrolizumab (MK3475) * Abemaciclib (LY2835219)

Timeline

Start

2021-12-01

Primary completion

2023-12-01

Completion

2024-12-01

Drugs

Indications